{
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2935, 
        2949
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3183, 
        3197
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3429, 
        3443
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4015, 
        4029
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4199, 
        4222
      ]
    }
  ], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2843, 
        2870
      ]
    }
  ], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        444, 
        473
      ]
    }
  ], 
  "Microscopic Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2353, 
        2388
      ]
    }
  ], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2916, 
        2924
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3092, 
        3098
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3164, 
        3172
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3337, 
        3343
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3410, 
        3418
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3584, 
        3590
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3656, 
        3662
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3923, 
        3929
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3996, 
        4004
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4169, 
        4175
      ]
    }
  ], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2925, 
        2934
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3099, 
        3115
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3173, 
        3182
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3344, 
        3360
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3419, 
        3428
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3591, 
        3607
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3663, 
        3679
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3930, 
        3946
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4005, 
        4014
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4176, 
        4192
      ]
    }
  ], 
  "Relative Location (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2892, 
        2902
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3069, 
        3079
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3141, 
        3150
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3315, 
        3324
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3386, 
        3396
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3561, 
        3571
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3633, 
        3642
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3705, 
        3714
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3803, 
        3811
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3902, 
        3910
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        3973, 
        3982
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        4147, 
        4156
      ]
    }
  ], 
  "Specimen Identifier (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        2872, 
        2873
      ]
    }
  ], 
  "__text": "MSH|^~\\&|PATHLAB_LIS|HOSPITAL 11^9311^MOH|PIMS|CCO|20160602092435|A85A9D8A1D8B480AFF287A54FEE0F15AC36DC6DE|ORU^R01|99999999999999999999|P|2.5|||||\nPID|1||^^^^MRN^HOSPITAL 11&9999&MOH~9999999999&LB&ON^^^^JHN||XXXXX^XXX^XXXXXX||99999999|M||||||||||||||||||||||N|\nOBR|1||BZ00605522|11529-5^Surgical Pathology Study Report^LN^BX^Biopsy^L|||20160517|||68091^XXXXXXX^XXXXXXXX^XXX^^XX.||||||||||||20160602|||C|||||||99999^XXXXX^XXXXX^XXXX^^XX|\n\n\n\n\n\n\n\nPath report.gross description\n\n1.Specimen consists of 2 tan tissue coresnE\\measuring 5 and 12 mm in length by less than 1 mmnE\\in diameter and no fragments. Embedded in toto.nE\nE\\2.Specimen consists of 1 tan tissue corenE\\measuring 15 mm in length by less than 1 mm innE\\diameter and no fragments. Embedded in toto.nE\nE\\3.Specimen consists of 1 tan tissue corenE\\measuring 14 mm and 1 fragment measuring in totalnE\\4 mm in length by less than 1 mm in diameter.nE\\Embedded in toto.nE\nE\\4.Specimen consists of 3 tan tissue coresnE\\measuring 5, 5, and 14 mm in length by less thannE\\1 mm in diameter and no fragments. Embedded innE\\toto.nE\nE\\5.Specimen consists of 1 tan tissue corenE\\measuring 11 mm and 3 fragments measuring innE\\total 7 mm in length by less than 1 mm innE\\diameter. Embedded in toto.nE\nE\nE\\6.Specimen consists of 1 tan tissue corenE\\measuring 16 mm and 2 fragments measuring innE\\total 5 mm in length by less than 1 mm innE\\diameter. Embedded in toto.nE\nE\\7.Specimen consists of 1 tan tissue corenE\\measuring 27 mm in length by less than 1 mm innE\\diameter and no fragments. Embedded in toto.nE\nE\\8.Specimen consists of 1 tan tissue corenE\\measuring 14 mm and 1 fragment measuring in totalnE\\2 mm in length by less than 1 mm in diameter.nE\\Embedded in toto.nE\nE\\9.Specimen consists of 1 tan tissue corenE\\measuring 17 mm in length by less than 1 mm innE\\diameter and no fragments. Embedded in toto.nE\nE\\10.Specimen consists of 1 tan tissue corenE\\measuring 10 mm and 2 fragments measuring innE\\total 4 mm in length by less than 1 mm innE\\diameter. Embedded in toto.nE\nE\\11.Specimen consists of 2 tan tissue coresnE\\measuring 8 and 20 mm in length by less than 1 mmnE\\in diameter and no fragments. Embedded in toto.nE\nE\\12.Specimen consists of 2 tan tissue coresnE\\each measuring 10 mm and 1 fragment measuring innE\\total 4 mm in length by less than 1 mm innE\\diameter. Embedded in toto.nE\\\n\n\nPath report.microscopic observation\n\nTumour TypenE\\adenocarcinoma, conventional typenE\nE\\ExtentnE\\# sites involved/total sites  4 / 12nE\\# cores involved/total cores  4 / 12nE\\overall % tissue involved  8%nE\\% involvement in mostnE\\extensively involved core  70%nE\nE\\GleasonnE\\Overall Gleason Score (1?, worst)6 (3, 3)nE\\Highest Gleason Score (any site)6 (3, 3)nE\\% Gleason patterns 4, 5  0%nE\nE\\OthernE\\Perineural invasion  not identifiednE\\Periprostatic fat invasion  not identifiednE\\\n\n\nPath report.final diagnosis\n\n1.BIOPSY, PROSTATE (RIGHT BASE LATERAL)nE\\- INVASIVE PROSTATIC ADENOCARCINOMA; GLEASONnE\\SCORE 6/10 (PRIMARY 3, SECONDARY 3); 1/1 COREnE\\INVOLVED; 5-10% TISSUE INVOLVEMENT.nE\nE\\2.BIOPSY, PROSTATE (RIGHT BASE MEDIAL)nE\\- BENIGN PROSTATIC TISSUE.nE\nE\\3.BIOPSY, PROSTATE (RIGHT MID LATERAL)nE\\- INVASIVE PROSTATIC ADENOCARCINOMA; GLEASONnE\\SCORE 6/10 (PRIMARY 3, SECONDARY 3); 1/1 COREnE\\INVOLVED; 70% TISSUE INVOLVEMENT.nE\nE\\4.BIOPSY, PROSTATE (RIGHT MID MEDIAL)nE\\- BENIGN PROSTATIC TISSUE.nE\nE\\5.BIOPSY, PROSTATE (RIGHT APEX LATERAL)nE\\- INVASIVE PROSTATIC ADENOCARCINOMA; GLEASONnE\\SCORE 6/10 (PRIMARY 3, SECONDARY 3); 1/1 COREnE\\INVOLVED; 20% TISSUE INVOLVEMENT.nE\nE\\6.BIOPSY, PROSTATE (RIGHT APEX MEDIAL)nE\\- BENIGN PROSTATIC TISSUE.nE\nE\\7.BIOPSY, PROSTATE (LEFT BASE LATERAL)nE\\- BENIGN PROSTATIC TISSUE.nE\nE\\8.BIOPSY, PROSTATE (LEFT BASE MEDIAL)nE\\- FOCAL GLANDULAR ATROPHY, NEGATIVE FORnE\\MALIGNANCY.nE\nE\\9.BIOPSY, PROSTATE (LEFT MID LATERAL)nE\\- FOCAL GLANDULAR ATROPHY, NEGATIVE FORnE\\MALIGNANCY.nE\nE\\10.BIOPSY, PROSTATE (LEFT MID MEDIAL)nE\\- BENIGN PROSTATIC TISSUE.nE\nE\\11.BIOPSY, PROSTATE (LEFT APEX LATERAL)nE\\- INVASIVE PROSTATIC ADENOCARCINOMA; GLEASONnE\\SCORE 6/10 (PRIMARY 3, SECONDARY 3); 1/1 COREnE\\INVOLVED; 2% TISSUE INVOLVEMENT.nE\nE\\12.BIOPSY, PROSTATE (LEFT APEX MEDIAL)nE\\- BENIGN PROSTATIC TISSUE.nE\\\n\n\nPath report.relevant Hx\n\nPSA Total: 5.06 ng/mLnE\nE\\Family History / Other: On active surveillancenE\\\n\n\n"
}